Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state

Addiction

Volumn 112, Issue 12, 2017, Pages 2167-2177

  Smart, Rosanna ^a   Caulkins, Jonathan P ^a,b   Kilmer, Beau ^a   Davenport, Steven ^a   Midgette, Greg ^a  

^a RAND CORPORATION   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Cannabis; drug policy; hedonic models; legalization; potency; prices

Indexed keywords

CANNABIS;

CANNABIS USE; CHEMISTRY; COMMERCIAL PHENOMENA; DRUG LEGISLATION; ECONOMICS; HUMAN; LEGISLATION AND JURISPRUDENCE; STATISTICS AND NUMERICAL DATA; WASHINGTON;

CANNABIS; COMMERCE; HUMANS; LEGISLATION, DRUG; MARIJUANA USE; WASHINGTON;

EID: 85021845669     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13886     Document Type: Article

References (67)

1. McLellan A. A., Ware M. A., Boyd S., Chow G., Jesso M., Kendall P. et al. A Framework for the Legalization and Regulation of Cannabis in Canada: The Final Report of the Task Force on Cannabis Legalization and Regulation. Ottawa, ON: Health Canada; 2016.
2. Buckley W. F. The war on drugs is lost. Nat Rev 1996; 48: 34–48.
3. Smith N. High potency cannabis: the forgotten variable. Addiction 2005; 100: 1558–1560.
4. Ramaekers J. G., Kauert G., van Ruitenbeek P., Theunissen E. L., Schneider E., Moeller M. R. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006; 31: 2296–2303.
5. Di Forti M., Marconi A., Carra E., Fraietta S., Trotta A., Bonomo M. et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case–control study. Lancet Psychiatry 2015; 2: 233–238.
6. Hall W., Degenhardt L. High potency cannabis. BMJ 2015; 350: h1205.
7. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015; 110: 19–35.
8. Volkow N. D., Baler R. D., Compton W. M., Weiss S. R. B. Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219–2227.
9. Hill K. P. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 2015; 313: 2474–2483.
10. Whiting P. F., Wolff R. F., Deshpande S., Di Nisio M., Duffy S., Hernandez A. V. et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313: 2456–2473.
11. Volkow N. D., Swanson J. M., Evins A. E., Delisi L. E., Meier M. H., Gonzalez R. et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 2016; 73: 292–297.
12. Englund A., Freeman T. P., Murray R. M., McGuire P. Can we make cannabis safer? Lancet Psychiatry 2017; https://doi.org/10.1016/S2215-0366(17)30075-5.
13. Freeman T., Winstock A. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 2015; 45: 3181–3189.
14. Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T. R. et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195: 488–491.
15. Daniulaityte R., Nahhas R. W., Wijeratne S., Carlson R. G., Lamy F. R., Martins S. S. et al. ‘time for dabs’: analyzing twitter data on marijuana concentrates across the US. Drug Alcohol Depend 2015; 155: 307–311.
16. Krauss M. J., Sowles S. J., Mylvaganam S., Zewdie K., Bierut L. J., Cavazos-Rehg P. A. Displays of dabbing marijuana extracts on YouTube. Drug Alcohol Depend 2015; 155: 45–51.
17. Loflin M., Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav 2014; 39: 1430–1433.
18. Morean M. E., Kong G., Camenga D. R., Cavallo D. A., Krishnan-Sarin S. High school students’ use of electronic cigarettes to vaporize cannabis. Pediatrics 2015; 136: 611–616.
19. Raber J. C., Elzinga S., Kaplan C. Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci 2015; 40: 797–803.
20. Stogner J. M., Miller B. L. Assessing the dangers of ‘dabbing’: mere marijuana or harmful new trend? Pediatrics 2015; 136: 1–3.
21. Murphy F., Sales P., Murphy S., Averill S., Lau N., Sato S.-O. Baby boomers and cannabis delivery systems. J Drug Issues 2015; 45: 293–313.
22. Hall W., Lynskey M. Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. Lancet Psychiatry 2016; 3: 900–906.
23. Pacula R. L., Smart R. Medical marijuana and marijuana legalization. Annu Rev Clin Psychol 2017; 13: 397–419.
24. Van Der Pol P., Liebregts N., Brunt T., Amsterdam J., Graaf R., Korf D. J. et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 2014; 109: 1101–1109.
25. Freeman T. P., Morgan C. J., Hindocha C., Schafer G., Das R. K., Curran H. V. Just say ‘know’: how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints? Addiction 2014; 109: 1686–1694.
26. Cole J. C., Goudie A. J., Field M., Loverseed A.-C., Charlton S., Sumnall H. R. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug Alcohol Depend 2008; 94: 183–190.
27. Ben Lakhdar C., Vaillant N. G., Wolff F.-C. Price elasticity of demand for cannabis: does potency matter? Addict Res Theory 2016; 24: 300–312.
28. Ben Lakhdar C. The determinants of cannabis pricing: between credence, brand name, and individuals characteristics’ users. Vienna, Austria: Proceedings of the 3rd annual ISSDP Conference; 2009.
29. Caulkins J., Andrzejewski S., Dahlkemper L. How much will the 25/25/25 tax scheme actually impact the price of cannabis? Supplement: Retail and processor markup. Los Angeles, CA: BOTEC Analysis Corp.; 2013.
30. Washington State Liquor and Cannnabis Board. Medical Marijuana FAQs. Olympia, WA: Washington State Liquor and Cannabis Board; 2016.
31. Washington State Department of Revenue. Marijuana retailers—medical endorsement. Olympia, WA: Washington State Liquor and Cannabis Board; 2016.
32. Washington State Liquor and Cannnabis Board. Weekly marijuana report, December 12, 2016. Olympia, WA: Washington State Liquor and Cannabis Board; 2016.
33. Rosen S. Hedonic prices and implicit markets: product differentiation in pure competition. J Polit Econ 1974; 82: 34–55.
34. Young B. Some pot labs in state failed no pot at all, says scientist. Marijuana [document on the Internet]. Seattle Times; 2016 Jan 5. Available at: http://www.seattletimes.com/seattle-news/marijuana/some-pot-labs-in-state-failed-no-pot-at-all-says-scientist/ (accessed 1 February 2017) (Archived at http://www.webcitation.org/6rXK3vAQx).
35. Baca R. Lab: Edibles' potency more accurate than a year ago, still needs work. Marijuana [document on the Internet]. Denver Post; 2015 April 11. Available at: http://www.denverpost.com/2015/04/11/lab-edibles-potency-more-accurate-than-a-year-ago-still-needs-work/ (accessed 1 February 2017) (Archived at http://www.webcitation.org/6rXKNJXbh).
36. McCall K. Approval to File Emergency Rules to Implement 2015 Marijuana Legislation. Olympia, WA: Washington State Liquor and Cannabis Board; 2016.
37. Young B. State suspends license of Poulsbo pot-test lab. Marijuana [document on the Internet]. Seattle Times; 2016 April 18. Available at: http://www.seattletimes.com/seattle-news/marijuana/state-suspends-license-of-poulsbo-pot-test-lab/ (accessed 1 February 2017) (Archived at http://www.webcitation.org/6rXKZ4cID).
38. Bertrand M., Duflo E., Mullainathan S. How much should we trust differences-in-differences estimates? Q J Econ 2004; 119: 249–275.
39. R Development Core Team. R: a Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.
40. Statacorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015.
41. Sevigny E. L. Is today's marijuana more potent simply because it's fresher? Drug Test Anal 2013; 5: 62–67.
42. Kilmer B., Everingham S. S., Caulkins J. P., Midgette G., Pacula R. L., Reuter P. et al. What America's users spend on illegal drugs, 2000–2010. Prepared for the Office of National Drug Control Policy. Washington, DC: Executive Office of the President; 2014.
43. Niesink R. J., Rigter S., Koeter M. W., Brunt T. M. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15. Addiction 2015; 110: 1941–1950.
44. Maa E., Figi P. The case for medical marijuana in epilepsy. Epilepsia 2014; 55: 783–786.
45. Caulkins J. P., Padman R. Quantity discounts and quality premia for illicit drugs. J Am Statist Assoc 1993; 88: 748–757.
46. Clements K. W. Pricing and packaging: the case of marijuana. J Bus 2006; 79: 2019–2044.
47. Caulkins J. P., Gurga B., Little C. Economic analysis of drug transaction ‘cycles’ described by incarcerated UK drug dealers. Global Crime 2009; 10: 94–112.
48. Mehmedic Z., Chandra S., Slade D., Denham H., Foster S., Patel A. S. et al. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209–1217.
49. Van Laar M., Van Der Pol P., Niesink R. Limitations to the Dutch cannabis toleration policy assumptions underlying the reclassification of cannabis above 15% THC. Int J Drug Policy 2016; 34: 58–64.
50. Cowan R. How the narcs created crack. Natl Rev 1986; 38: 26–31.
51. Maccoun R. J. Commentary on Niesink et al. (2015): interpreting trends in tetrahydrocannabinol potency—three stories, one of which may be true. Addiction 2015; 110: 1951–1952.
52. Thornton M. The Economics of Prohibition. Salt Lake City, UT: University of Utah Press; 1991.
53. Thornton M. The potency of illegal drugs. J Drug Issues 1998; 28: 725–740.
54. Subritzky T., Pettigrew S., Lenton S. Issues in the implementation and evolution of the commercial recreational cannabis market in Colorado. Int J Drug Policy 2016; 27: 1–12.
55. Lee D. C., Crosier B. S., Borodovsky J. T., Sargent J. D., Budney A. J. Online survey characterizing vaporizer use among cannabis users. Drug Alcohol Depend 2016; 159: 227–233.
56. Etter J.-F. Electronic cigarettes and cannabis: an exploratory study. Eur Addict Res 2015; 21: 124–130.
57. Malouff J. M., Rooke S. E., Copeland J. Experiences of marijuana-vaporizer users. Subst Abus 2014; 35: 127–128.
58. Zhu S.-H., Gamst A., Lee M., Cummins S., Yin L., Zoref L. The use and perception of electronic cigarettes and snus among the US population. PLOS ONE 2013; 8: e79332.
59. Kilmer B. Recreational cannabis—minimizing the health risks from legalization. N Engl J Med 2017; 376: 705–707.
60. Reuter P., Caulkins J. P. Illegal ‘lemons’: price dispersion in cocaine and heroin markets. Bull Narc 2004; 56: 141–165.
61. Pratt J. W., Wise D. A., Zeckhauser R. Price differences in almost competitive markets. Q J Econ 1979; 93: 189–211.
62. Walsh P. P., Whelan C. Modelling price dispersion as an outcome of competition in the Irish grocery market. J Ind Econ 1999; 47: 325–343.
63. Treno A. J., Nephew T. M., Ponicki W. R., Gruenewald P. J. Alcohol beverage price spectra: opportunities for substitution. Alcohol Clin Exp Res 1993; 17: 675–680.
64. Caulkins J. P., Pacula R. L. Marijuana markets: inferences from reports by the household population. J Drug Issues 2006; 36: 173–200.
65. Pen S. E. Quality-Constant Illicit Drug Prices. Perth: University of Western Australia Business School, Economics; 2012.
66. Carlini B. H., Garrett S. B., Harwick R. M. Beyond joints and brownies: marijuana concentrates in the legal landscape of WA state. Int J Drug Policy 2017; 42: 26–29.
67. Caulkins J. P., Kilmer B., Maccoun R. J., Pacula R. L., Reuter P. Design considerations for legalizing cannabis: lessons inspired by analysis of California's proposition 19. Addiction 2012; 107: 865–871.